Search Results

Zhuang, Y., et al., Structural insights into the human D1 and D2 dopamine receptor signaling complexes Hu, Y., et al., Identification of a five-gene signature of the RGS gene family with prognostic value

Impact of GRK3 on YAP1 and its targets was determined."

Adapted from: Zhang Y, Tang H, Chen W, Zhang J.

M., Pérez-Hernández, G., Batebi, H., Gao, Y., Eskici, G., Seven, A.

Hello Readers👋, We're excited to share our weekly newsletter with you. with the latest research and advancements in the field with our convenient, weekly news delivered to your You can always adjust your email preferences in your account settings. Below is your Classified GPCR News at a glance for January 9th to January 15th, 2023. and more Isolation and functional identification of secretin family G-protein coupled receptor from Y-organ

in a wide range of inflammatory, autoimmune and infectious diseases (Proudfoot 2002), and in recent years immunosuppressive tumor microenvironment, and facilitate metastatic spread (Nagarsheth, Wicha, and Zou

Shocking GPCR revelations await you. Donna Matzov ,  Dominic R Huxley ,   Peter Gmeiner ,  Peter J McCormick ,  Dorothee Weikert ,  Masha Y A single platform to connect from anywhere in the world  And if you go for a Premium Membership , you'll Thank you for your understanding and support! Get your 5-day free trial TODAY!

Allosteric Interactions When should you push the native system—and when should you partner with it? If your team is arguing about “potency vs. effect size vs. duration,” this is your playbook for aligning Your membership gives you:   📚 Proven frameworks for real-world discovery 🌍 Flexible, on-demand lessons you—in the best possible way—is the day you know you’re onto something. B y integrating them into GPCR workflows, discovery teams can accelerate identification, characterization

ligand binding, receptor activation, desensitization and trafficking is the apelin receptor (APJ) (Y.

These results underscore how the type of assay can yield different results and how critical information Y.; Fan, H.; Wei, Z.; Zhang, C. Orthosteric and Allosteric Action of the C5a Receptor Antagonists.

If you'd like to showcase your work, please email us at Hello@DrGPCR.com. We look forward to seeing you in a few days at the Molecular Pharmacology GRC and the associated Molecular Yamina Berchiche, our founder. Below is your Classified GPCR News at a glance for May 29th to June 4th, 2023. Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration

If you are curious about the material and methods or want more information, here is the published article W.; Högl, B.; Bainbridge, J.; Buchfuhrer, M.; Hadjigeorgiou, G.; Inoue, Y.; Manconi, M.; Oertel, W.; Springer Netherlands: Dordrecht, 2014; pp 55–74. https://doi.org/10.1007/978-94-007-7423-0_4 . (12)      Yung-Chi Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y1 Receptor. J.

We'll see you in Mexico City! Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav What is your backstory? Don’t be surprised if you find yourself singing Daddy Yankee’s “Gasolina” from the top of your lungs while executing your best perreo or Luis Enrique’s “Yo no sé mañana” while a stranger takes you floating

mutant-as-the-basis-for-personalized-high-throughput-drug-screening References Grimes, J., Koszegi, Z., Lanoiselée, Y.

Nature communications, 8(1), 443. https://doi.org/10.1038/s41467-017-00357-2 Jong, Y. Z., Wilderman, A., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., Liu, D., Feigin, M

6P4]CCL5), a chemokine antagonist ([5P7]CCL5), and a small-molecule inverse agonist (maraviroc) (Tan, Zhu there are four distinct pathways through which structural alterations in the binding site influence Y2446.44 hydrogen bonding to E2837.39 by A4 of CCL3; c) Route 3 - characterized by steric effects between TM2 and Y3 In ACKR3, the presence of a tyrosine at position 6.40 plays a role in its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han, Tachado et al. 2012, Yen,

funding into small biotech companies developing novel technology platforms to target GPCRs in recent years Within the last two years, three investments stand out: · Tectonic Therapeutics: received $80 platform (summarized in Figure 2) can be used to complete a discovery campaign within only 6-12 months, yielding There is a great deal of scientific and business interest in solving this problem, and the last two years fully integrated PROcisionXᵀᴹ discovery platform Structure-based validation of Orion’s approach Zheng, Y.

In this session, you’ll gain: How pharmacology translates assay signals into biological predictions Why But pharmacology asks a different question: How will this molecule behave in a system we have not yet Your job as a pharmacologist is to guide them with solid data. Yet failure is not a sign of weakness in discovery science.

Heidelberg: Berlin, Heidelberg, 2009; Vol. 193, pp 1–24. https://doi.org/10.1007/978-3-540-89615-9_1 . (8) Yung-Chi

This post is your one-stop hub — agenda highlights, who's attending, our exclusive discount code, and The human genome encodes ~800 GPCRs, yet only around 15% are currently targeted by approved drugs — leaving This year's program reflects where science is actually heading. Dr. GPCR founder Dr. Yamina Berchiche will be there — if you're attending, reach out to connect. GPCR Drug Discovery Agenda Highlights: What's New in 2026 This year's summit runs across three days —

In this session, you’ll gain: A framework for cancelling cell effects to isolate true receptor selectivity Without full curves, you cannot separate drug properties from detection limitations. In the full lecture, you will learn how this approach removes subjectivity from interpretation. Those who master system-independent thinking today will define tomorrow’s breakthroughs. 40 years of expertise at your fingertips: Explore the full library and trailers ➤ https://www.ecosystem.drgpcr.com

The real challenge for biotech leaders is simple and demanding at the same time: 👉 How do you stay ambitious Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company

Terry’s Corner Expands to YouTube Terry’s Corner is now on YouTube. Forty years of pharmacological expertise — organized into a year-round framework for serious GPCR scientists Stay in the Know If you want updates on future AMAs, new YouTube releases, white papers, and ongoing If you want structured, year-round access to Terry’s full library — including advanced lectures, archived AMAs, and quantitative pharmacology deep dives: 👉 Access Terry’s Corner Free for 7 Days Strengthen Your

Saying yes often feels safer than saying no. you start pitching. Ready to Break Your Bottlenecks? Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company

Ask your questions in real time — then revisit the material anytime. Structured continuity.   As new masterclasses launch, your access expands automatically. Faculty and their immediate teams receive one year of complimentary Premium Membership. Explore Dr. GPCR Premium Membership Gives You an Edge GPCR drug discovery is accelerating — across obesity, CNS, GPCR Premium — Build Your Structured Advantage ➤

Drawing on more than 25 years of GPCR expertise, Eurofins DiscoverX delivers one of the industry’s most Yamina Berchiche, Founder and CEO of Dr. GPCR . With more than 25 years of expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX

The next live AMA will take place: Thursday, February 26th at 12:00 PM EST You are invited to submit Yet rare adverse effects may only emerge after large-scale exposure, and selectivity must still be demonstrated Forty years of pharmacological expertise — organized into a year-round learning framework for serious

This is not a cash crisis yet. It is a loss of financial control . It tells you how fast cash is leaving the company, but it does not tell you how many meaningful choices Ready to Break Your Bottlenecks? Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company

If you work in GPCR research, clarity is leverage. You can now search courses by level, topic, or instructor. Align your team around structured learning outcomes, not scattered slide decks. Submit your work today ➤ Why Dr. Equip your team with repeatable training resources in one place.

. 👉 None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech Yet clarity erodes, because reaction has replaced deliberate choice. The real work is deciding clearly before pressure decides for you. Ready to Break Your Bottlenecks? Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company